Biologics in treatment of lupus nephritis
10.3760/cma.j.cn441217-20221117-01135
- VernacularTitle:生物制剂在狼疮肾炎治疗中的应用
- Author:
Wenzhuo YANG
1
;
Xin WANG
;
Wei CHEN
;
Zhijian LI
Author Information
1. 中山大学附属第一医院肾内科，广州 510080
- Keywords:
Lupus erythematosus, systemic;
Lupus nephritis;
Biological factors;
Therapeutics
- From:
Chinese Journal of Nephrology
2023;39(7):552-558
- CountryChina
- Language:Chinese
-
Abstract:
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes damage to multiple vital tissues and target organs, and lupus nephritis (LN) is a serious complication of SLE involving the kidneys. The use of glucocorticoids and immunosuppressants has been dominant in the treatment strategy of LN, while their adverse effects have also raised concerns. In recent years, the development and use of biologics have provided new ideas for the treatment of LN and have also achieved positive efficacy in several clinical trials in SLE and LN. Biologics can be divided into monoclonal antibodies and recombinant proteins, which exert therapeutic effects on SLE and LN through a variety of mechanisms at the cellular-molecular level. In this article, we review recent research advances in the treatment of SLE and LN from the perspective of the different mechanisms of action of biologics.
